These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20505673)

  • 1. Cardioprotective properties of bradykinin: role of the B(2) receptor.
    Manolis AJ; Marketou ME; Gavras I; Gavras H
    Hypertens Res; 2010 Aug; 33(8):772-7. PubMed ID: 20505673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct.
    Marketou M; Kintsurashvili E; Papanicolaou KN; Lucero HA; Gavras I; Gavras H
    Am J Hypertens; 2010 May; 23(5):562-8. PubMed ID: 20186129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.
    Freise H; Palmes D; Spiegel HU
    J Surg Res; 2006 Aug; 134(2):231-7. PubMed ID: 16513137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice.
    Messadi-Laribi E; Griol-Charhbili V; Gaies E; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):489-93. PubMed ID: 18307747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors.
    Juggi JS; Koenig-Berard E; Van Gilst WH
    Can J Cardiol; 1993 May; 9(4):336-52. PubMed ID: 8513428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bradykinin B2 receptors as a target in diabetic nephropathy.
    Doggrell SA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):251-5. PubMed ID: 16555685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury.
    Casillas-Ramirez A; Amine-Zaouali M; Massip-Salcedo M; Padrissa-Altés S; Bintanel-Morcillo M; Ramalho F; Serafín A; Rimola A; Arroyo V; Rodés J; Roselló-Catafau J; Peralta C
    Crit Care Med; 2008 Apr; 36(4):1256-66. PubMed ID: 18379253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC
    Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bradykinin in ischemia-reperfusion injury of the rat lung.
    Nowak K; Weih S; Post S; Gebhard MM; Hohenberger P
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):513-22. PubMed ID: 18204165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
    Messadi-Laribi E; Griol-Charhbili V; Pizard A; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C
    J Pharmacol Exp Ther; 2007 Oct; 323(1):210-6. PubMed ID: 17636004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
    Seccia TM; Belloni AS; Guidolin D; Sticchi D; Nussdorfer GG; Pessina AC; Rossi GP
    J Hypertens; 2006 Jul; 24(7):1419-27. PubMed ID: 16794493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W; Martorana PA; Schölkens BA
    J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors.
    Duka A; Kintsurashvili E; Duka I; Ona D; Hopkins TA; Bader M; Gavras I; Gavras H
    Hypertension; 2008 May; 51(5):1352-7. PubMed ID: 18347228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardioactive hormones: bradykinin].
    Dendorfer A; Simon M; Dominiak P
    Z Kardiol; 1996; 85 Suppl 6():211-8. PubMed ID: 9064968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of angiotensin I converting enzyme inhibitor on post-ischemic contractile function of perfused rat heart.
    Tanonaka K; Kamiyama T; Takezono A; Sakai K; Takeo S
    J Mol Cell Cardiol; 1996 Aug; 28(8):1659-70. PubMed ID: 8877776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.